Deletion of exon 7 of CD163 gene in domestic pigs

Manufacturer
Genus plc | ABS Global Inc | PIC USA Inc
Effective date
2025-10-03
Label type
INTENTIONAL ANIMAL GENOMIC ALTERATION LABEL
Version
2
Source
full-release
Hydrated at
2026-06-01 02:52:47

Label at a glance#

ProductDeletion of exon 7 of CD163 gene in domestic pigs
Active ingredientDeletion of exon 7 of CD163 gene in domestic pigs
Label structure7 sections

Label contents#

Full prescribing information#

1. DESCRIPTION

DESCRIPTION SECTION

1.1 Product Identification

Deletion of exon 7 of CD163 gene (abbreviated CD163ΔE7) in domestic pigs (Sus scrofa domesticus). Breeding lines containing one copy (heterozygous) or two copies (homozygous) of CD163ΔE7 may be identified with the registered tradename “EverThrive™ PRP”. However, only pigs carrying two copies of CD163ΔE7 (homozygous) are intended to be resistant to Porcine Reproductive and Respiratory Syndrome Virus (PRRSV).

1.2 Product Claim

Deletion of exon 7 of the CD163 gene in domestic pigs (Sus scrofa domesticus) is intended to confer resistance to porcine reproductive and respiratory syndrome virus (PRRSV) in homozygous pigs. Pigs carrying one or two copies of CD163ΔE7, and their offspring, are intended for breeding or to be used as sources of food.

1.3 Uses

Product Label 1: Homozygous Pigs.

Pigs bearing this label are CD163ΔE7 homozygous and are resistant to PRRSV.

Resistance to PRRSV in the progeny of this pig (and from semen derived from this pig) is affected by the genetic background of the other parent pig it is bred to:

     • If the other parent is CD163ΔE7 homozygous (two copies), all progeny will be resistant to PRRSV.
     • If the other parent is CD163ΔE7 heterozygous (one copy), approximately one half of the progeny will be resistant to PRRSV.
     • If the other parent has no CD163ΔE7, none of the progeny will be resistant to PRRSV.

Product Label 2: Semen from Homozygous Pigs.

Semen bearing this label will produce offspring that may or may not be resistant to PRRSV.

Resistance to PRRSV in the progeny of this semen is affected by the genetic background of the other parent pig it is bred to:

     • If the other parent is CD163ΔE7 homozygous (two copies), all progeny will be resistant to PRRSV.
     • If the other parent is CD163ΔE7 heterozygous (one copy), approximately one half of the progeny will be resistant to PRRSV.
     • If the other parent has no CD163ΔE7, none of the progeny will be resistant to PRRSV.

Product Label 3: Heterozygous Pigs.

Pigs bearing this label are CD163ΔE7 heterozygous and are not resistant to PRRSV.

Resistance to PRRSV in the progeny of this pig (and from semen derived from this pig) is affected by the genetic background of the other parent pig it is bred to:

     • If the other parent is CD163ΔE7 homozygous (two copies), approximately one half of the progeny will be resistant to PRRSV.
     • If the other parent is CD163ΔE7 heterozygous (one copy), approximately one in four of the progeny will be resistant to PRRSV.
     • If the other parent has no CD163ΔE7, none of the progeny will be resistant to PRRSV.

Product Label 4: Semen from Heterozygous Pigs.

Semen bearing this label will produce offspring that may or may not be resistant to PRRSV.

Resistance to PRRSV in the progeny of this semen is affected by the genetic background of the other parent pig it is bred to:

     • If the other parent is CD163ΔE7 homozygous (two copies), approximately one half of the progeny will be resistant to PRRSV.
     • If the other parent is CD163ΔE7 heterozygous (one copy), approximately one in four of the progeny will be resistant to PRRSV.
     • If the other parent has no CD163ΔE7, none of the progeny will be resistant to PRRSV.

Product Label 5: Ungenotyped Pigs.

Pigs bearing this label may contain one, two or no copies of CD163ΔE7 and are of unknown resistance to PRRSV.

2. WARNINGS AND PRECAUTIONS

SPL UNCLASSIFIED SECTION

Product Labels 1 and 3.

Deletion of exon 7 of the CD163 gene is a recessive genetic trait and only confers resistance to PRRSV in homozygous pigs (two copies). Pigs bearing this label will produce offspring that may or may not be resistant to PRRSV. See 1.3 Uses for additional information.

Product Labels 2 and 4.

Deletion of exon 7 of the CD163 gene is a recessive genetic trait and only confers resistance to PRRSV in homozygous pigs (two copies). Semen bearing this label will produce offspring that may or may not be resistant to PRRSV. See 1.3 Uses for additional information.

Product Label 5.

Deletion of exon 7 of the CD163 gene is a recessive genetic trait and only confers resistance to PRRSV in homozygous pigs (two copies). Pigs bearing this label may contain one, two or no copies of the CD163ΔE7 gene and are of unknown resistance to PRRSV. Pigs bearing this label will produce offspring that may or may not be resistant to PRRSV. See 1.3 Uses for additional information.

3. EFFECTIVENESS

SPL UNCLASSIFIED SECTION

In six live animal viral challenge studies, CD163ΔE7 homozygous pigs of multiple consecutive generations demonstrated resistance to infection following inoculation with one of seven PRRSV Type II isolates and two PRRSV Type I isolates. In these controlled studies consisting of 101 CD163ΔE7 homozygous pigs and 108 age-matched controls (CD163ΔE7 heterozygous pigs and pigs without a CD163 alteration), resistance to PRRSV infection was determined by demonstrating undetectable PRRSV RNA in serum samples (via PCR) and undetectable PRRSV antibody seroconversion (by ELISA) 21 days following viral inoculation. All CD163ΔE7 homozygous pigs were resistant to infection following inoculation with one of seven PRRSV Type II isolates and two PRRSV Type I isolates listed in Table 1, whereas no control pigs demonstrated resistance.

Table 1. Live Animal Viral Challenge Study Results Organized by PRRSV Inoculant

PRRSV Type and Lineage (if applicable)

PRRSV

Inoculant and RFLP*

(if applicable)

Number of CD163ΔE7

Homozygous IGA

Animals

Success Rate (%)**

in CD163ΔE7

Homozygous Animals

Number of Control Animals

Success Rate (%)**

in Control Animals

Type II, L8

NVSL97-7895

23

100

26

0

Type II, L1C

UIL21-0712 (RFLP 1-4-4)

21

100

16

0

Type II, L1H

USA/NE/2634- 1/2022 (RFLP

1-8-4)

5

100

5

0

Type II, L1A

USA/IN/65239- GA/2014 (RFLP 1-7-4)

5

100

5

0

Type II, L1E

USA/OK/2791- 12/2022 (RFLP

1-4-2)

5

100

5

0

Type II,

L1D

MLV vaccine

(RFLP 1-8-4)

5

100

5

0

Type II, L5

USA/IL/23295- GA-2022 (RFLP 2-5-2)

5

100

5

0

Type I

SD13-15

22

100

27

0

Type I

SD01-08

10

100

14

0

* RFLP = Restriction Fragment Length Polymorphism, a commonly used way of classifying PRRSV strains.

** Success rate is the proportion of animals with undetectable PRRSV RNA in serum samples and undetectable PRRSV antibody seroconversion on study day 21.

In two studies, two out of twenty-six CD163ΔE7 homozygous pigs demonstrated resistance following inoculation with a PRRSV Type II – KS06 inoculant (Table 2). The clinical relevance of the reported lack of resistance of CD163ΔE7 homozygous pigs to the KS06 isolate is undetermined; this isolate and the lineage to which it is classified were not reported in the commercial swine population of the United States at an appreciable level at the time of evaluation (2022-2023).

Table 2. Live Animal Viral Challenge Study Results Following PRRSV Type II – KS06 Inoculation

PRRSV

Type and Lineage

PRRSV

Inoculant

Number of CD163ΔE7

Homozygous IGA Animals

Success Rate (%)* in CD163ΔE7

Homozygous Animals

Number of Control Animals

Success Rate (%)* in Control Animals

Type II, L6

KS06-72109

26

8

22

0

* Success rate is the proportion of animals with undetectable PRRSV RNA in serum samples and undetectable PRRSV antibody seroconversion on study day 21.

4. TARGET ANIMAL SAFETY

SPL UNCLASSIFIED SECTION

In controlled farm studies, pigs containing two copies (homozygous) or one copy (heterozygous) of CD163ΔE7 showed no significant differences from unedited (null) pigs for most phenotypic characteristics observed across the lifecycle of the pigs. Differences observed between groups in the studies were not clinically significant and were consistent with reported ranges for commercial pigs.

Tables 3-4 summarize the results of the observational studies on pigs of Genus PIC elite breeding line L03. Similar data were collected for three additional breeding lines (L02, L65, and L800), demonstrating consistent safety outcomes across all lines studied.

Table 3. Phenotypic Characterization Across Life Stages

Least squares mean (LS Mean) and tests of significance among homozygous (CD163ΔE7/ΔE7), heterozygous edited (CD163ΔE7/+), and unedited (null, CD163+ /+) pigs for phenotypic characteristics across the lifecycle of the pigs. N (number of animals observed); BWT (individual piglet birth weight, kg); TEAT (total teat count); WT140 (individual bodweight of pig at 140 days of age, kg); LDG (lifetime daily gain, g per day); BF (ultrasound predicted 10th rib backfat depth, mm); LD (ultrasound predicted 10th rib loin depth, mm); *p < 0.05. **p < 0.01.

CD163ΔE7/ΔE7

CD163ΔE7/+

CD163+/+

Trait

N

LS

Mean

N

LS

Mean

N

LS

Mean

Early Life Traits

BWT

121

1.30

298

1.23

138

1.26

TEAT

121

15.91

298

16.16

138

15.97

FinishingTraits

WT140

55

93.17

58

88.41

55

88.77

LDG

55

636.96

58

614.38

55

611.83

BF

55

8.98

58

10.17**

55

9.99*

LD

55

63.54

58

64.60

55

65.09

Table 4. Female Reproductive Traits

Least squares mean (LS Mean) and tests of significance among homozygous (CD163ΔE7/ΔE7), heterozygous edited (CD163ΔE7/+), and unedited (null, CD163+/+) pigs for female reproductive traits. N (number of litters); GL (gestation length, days); TNB (total number of piglets born); NBA (number of piglets born alive per litter); NBD (number of piglets born dead per litter); MUM (number of mummified piglets per litter). No differences were significant at the p < 0.05 level.

CD163ΔE7/ΔE7

CD163ΔE7/+

CD163+/+

Trait

N

LS

Mean

N

LS

Mean

N

LS

Mean

GL

6

116.2

6

116.5

6

116.8

TNB

6

12.7

6

12.7

6

13.3

NBA

6

11.8

6

11.7

6

13.0

NBD

6

0.8

6

1.0

6

0.3

MUM

6

0.2

6

0.0

6

0.0

In these studies, morbidity and mortality rates were calculated for each group at various life stages (pre-weaning, nursery, finishing, and reproductive). No clinically significant differences were observed between groups. Morbidity and mortality rates for all groups were consistent with reported ranges for commercial pigs.

Separately, larger populations of pigs were evaluated for morbidity and mortality. Table 5 shows summaries of morbidity and mortality data collected from a larger population of pigs that were homozygous CD163ΔE7 pigs.

Table 5. Mortality and morbidity rates of homozygous CD163ΔE7 pigs under normal Genus PIC production practices.

Percentage (Mean ± SD)

Mortality*

Adult breeding herd

0.2% ± 0.2%

Piglets, pre-weaning

5.0% ± 1.3%

Piglets, post-weaning

0.7% ± 0.6%

Morbidity**

Adult breeding herd

0.8% ± 0.3%

Piglets, post-weaning

12.5% ± 10.8%

Piglets, post-weaning

0.1% ± 0.1%

* Mortality was calculated as the number of mortality events (animals dead or culled for health reasons) in the given sub- population in one week relative to the total number of pigs from the sub-population in the same week, taken from farm-level data across two farms (July to December 2024).

** Morbidity was calculated as the number of morbidity events (animals treated for a morbidity) in the given sub-population in one week relative to the total number of pigs from the sub-population in the same week, taken from farm-level data across two farms (October to December 2024).

5. CONTACT INFORMATION

SPL UNCLASSIFIED SECTION

To report suspected adverse events or for technical assistance, contact Customer Support at 800-325-3398 or www.pic.com.

For additional information about adverse experience reporting, contact FDA at 1.888.FDA.VETS or www.fda.gov/reportanimalae.

6. NAME AND PLACE OF BUSINESS

SPL UNCLASSIFIED SECTION

Produced and distributed by Genus plc and PIC, its wholly owned U.S. subsidiary.

Genus plc
Matrix House
Basing View
Basingstoke, Hampshire
RG21 4DZ
United Kingdom

PIC
100 Bluegrass Commons Blvd, Suite #2200
Hendersonville, TN 37075

Revision Date: October 2025
Approved by FDA under NADA # 141-609

7. PACKAGE LABEL PRINCIPAL DISPLAY PANELS

PACKAGE LABEL.PRINCIPAL DISPLAY PANEL

Label 1: Homozygous Pigs

86205-001-01 Homozygous Pigs.jpg86205-001-01 Homozygous Pigs.jpg

Label 2: Semen from Homozygous Pigs

86205-001-02 Homozygous Semen86205-001-02 Homozygous Semen

Label 3: Heterozygous Pigs

86205-001-03 Heterozygous Pigs86205-001-03 Heterozygous Pigs

Label 4: Semen from Heterozygous Pigs

86205-001-04 Heterozygous Semen.jpg86205-001-04 Heterozygous Semen.jpg

Label 5: Ungenotyped Pigs

86205-001-05 Ungenotyped Pigs86205-001-05 Ungenotyped Pigs

DailyMed Package Descriptions#

Package NDC, Product, Description table
Package NDCProductDescriptionFormQuantityStrengthSPL version
86205-001-01Deletion of exon 7 of CD163 gene in domestic pigs1 [arb'U] in 1 NOT APPLICABLENOT APPLICABLE12
86205-001-02Deletion of exon 7 of CD163 gene in domestic pigs1 [arb'U] in 1 NOT APPLICABLENOT APPLICABLE12
86205-001-03Deletion of exon 7 of CD163 gene in domestic pigs1 [arb'U] in 1 NOT APPLICABLENOT APPLICABLE12
86205-001-04Deletion of exon 7 of CD163 gene in domestic pigs1 [arb'U] in 1 NOT APPLICABLENOT APPLICABLE12
86205-001-05Deletion of exon 7 of CD163 gene in domestic pigs1 [arb'U] in 1 NOT APPLICABLENOT APPLICABLE12

Products#

Every source-derived product name is available through these pages.

DailyMed product names page 1 of 1 · 1 matching rows.

NDC Codes#

Product NDC, Package NDC table
Product NDCPackage NDC
86205-00186205-001-01, 86205-001-02, 86205-001-03, 86205-001-04, 86205-001-05

Ingredients#

Every source-derived ingredient row is available through these pages.

DailyMed ingredient rows page 1 of 1 · 1 matching rows.

Source Document#

Source XML

Reported adverse events (FAERS/openFDA)#

Adverse event summaries are temporarily unavailable. Other product information remains available.